Over the past decades, global health has moved from discrete disease campaigns to major developmental strategies. However, medication affordability remains an important, unsolved challenge for industry and the global community. This effort requires coordinated actions by multiple stakeholders. Industry can play a specific role through responsible, differentiated pricing of medicines. Public policies should incentivize such pricing policies rather than discouraging them by external reference pricing or parallel trade. Providing opportunities for industry to invest in emerging markets sustainably, patients will benefit from greater access and support attainment of the UN Millennium Development Goals.Full details at the Journal of Commercial Biotechnology
Home Biotechnology Industry News Emerging Markets and Differential Pricing Policies: A Question of Global Health?